Cynosure Receives FDA Clearance for Cellulaze Cellulite Laser

Cynosure, Inc. (NASDAQ: CYNO) announced this week that the U.S. Food and Drug Administration has cleared the Company’s Cellulaze™ Workstation for commercial distribution, giving millions of American women the first minimally invasive solution in their battle against cellulite.

Cellulaze reduces cellulite – in just one treatment – by restoring the normal structure of the skin and underlying connective tissue. Cellulaze diminishes the lumpy pockets of fat, releases the areas of skin depression typifying cellulite and increases the elasticity and thickness of the skin.

When I received this announcement I immediately contacted Dr. Bruce Katz, one of the country’s leading cosmetic dermatologists. Come to find out, Dr. Katz’s Aesthetic Center, Juva, was one of the five sites that conducted the FDA trials and he was the only Dermatologist amongst the five doctors.  I asked him what his insights were on this new procedure, “Cellulaze will be a game changer for the treatment of cellulite, for it is the first time we can successfully treat this very common problem with only one session and have lasting results!” stated Bruce Katz M.D.

The team at Acara is in complete agreement with Dr. Katz, this is a complete “game changer” in this area.  Finally there is a FDA approved device offering a procedure that doesn’t require an extended commitment with ongoing treatments to reduce the signs of cellulite.  Take a look at the before and after photos in this announcement that was sent out by Cynosure.

If you are thinking about adding Cellulaze to your practice, please contact us at Acara.  We have developed a Cellulaze market launch program.  For more information, contact Mary Lyons, Director of Business Development at mlyons@acarapartners.com or give her a call at 203-488-0028 x314 or complete this form:

Name(required)

Email(required)

Website

Type of Practice(required)

Telephone

Submit

Δ